Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
$4.48
+0.6%
$3.97
$2.13
$10.00
$305.06M0.58838,598 shs171,680 shs
Neurogene Inc. stock logo
NGNE
Neurogene
$21.33
-1.5%
$19.15
$6.88
$74.49
$304.17M1.51251,117 shs13,371 shs
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$8.77
-2.3%
$7.97
$4.62
$13.47
$548.25M0.291.37 million shs5.92 million shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$2.02
-1.7%
$0.82
$0.13
$3.29
$251.79M2.044.94 million shs1.66 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
+4.46%+2.30%+12.37%+33.63%+104.13%
Neurogene Inc. stock logo
NGNE
Neurogene
-3.04%-2.70%+21.96%+56.62%-48.75%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-1.54%-1.97%-3.55%+16.80%-27.01%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-7.24%-14.23%+753.10%+192.02%+122.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
2.0863 of 5 stars
3.51.00.00.00.63.30.6
Neurogene Inc. stock logo
NGNE
Neurogene
3.0852 of 5 stars
4.42.00.00.00.01.70.6
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
3.3893 of 5 stars
2.04.00.04.11.51.70.6
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3.9152 of 5 stars
4.35.00.00.03.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3.00
Buy$15.00235.20% Upside
Neurogene Inc. stock logo
NGNE
Neurogene
2.75
Moderate Buy$46.17116.44% Upside
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
1.94
Reduce$8.23-6.12% Downside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.60
Moderate Buy$5.63179.33% Upside

Current Analyst Ratings Breakdown

Latest VOR, NGNE, CRVS, and SAGE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$12.00 ➝ $9.20
6/30/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$3.00
6/26/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Outperform
6/20/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.00
6/17/2025
Neurogene Inc. stock logo
NGNE
Neurogene
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$50.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.50
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetHold ➝ Hold$8.00 ➝ $9.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$12.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$8.00 ➝ $8.50
6/16/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
6/12/2025
Neurogene Inc. stock logo
NGNE
Neurogene
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$22.00 ➝ $26.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/A$0.51 per shareN/A
Neurogene Inc. stock logo
NGNE
Neurogene
$930K327.06N/AN/A$20.89 per share1.02
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$47.40M11.58N/AN/A$7.60 per share1.15
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$62.29M-$0.98N/AN/AN/AN/A-24.04%-13.90%8/5/2025 (Estimated)
Neurogene Inc. stock logo
NGNE
Neurogene
-$75.14M-$4.35N/AN/AN/AN/A-36.16%-32.51%8/8/2025 (Estimated)
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$400.67M-$5.80N/AN/AN/A-747.63%-68.99%-60.67%7/30/2025 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$1.51N/AN/AN/AN/AN/AN/AN/A

Latest VOR, NGNE, CRVS, and SAGE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Neurogene Inc. stock logo
NGNE
Neurogene
-$1.15N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.13N/AN/AN/AN/AN/A
7/30/2025Q2 2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$0.96N/AN/AN/A$16.69 millionN/A
5/9/2025Q1 2025
Neurogene Inc. stock logo
NGNE
Neurogene
-$1.05-$1.08-$0.03-$1.08N/AN/A
5/8/2025Q1 2025
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
-$0.13-$0.13N/A-$0.13N/AN/A
4/29/2025Q1 2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/AN/AN/AN/AN/A
Neurogene Inc. stock logo
NGNE
Neurogene
N/AN/AN/AN/AN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
N/A
4.90
4.90
Neurogene Inc. stock logo
NGNE
Neurogene
N/A
21.03
21.03
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/A
9.13
9.13
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
46.64%
Neurogene Inc. stock logo
NGNE
Neurogene
52.37%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
99.22%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
31.30%
Neurogene Inc. stock logo
NGNE
Neurogene
9.92%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
5.50%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
3068.17 million46.83 millionOptionable
Neurogene Inc. stock logo
NGNE
Neurogene
9014.26 million12.85 millionOptionable
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
69062.62 million59.18 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
140124.96 million65.45 millionNot Optionable

Recent News About These Companies

Vor Biopharma (NYSE:VOR) Upgraded at HC Wainwright
Vor Biopharma (NYSE:VOR) Gains Momentum S&P 500
Vor Biopharma Inc. Stock Grades - Barron's

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Corvus Pharmaceuticals stock logo

Corvus Pharmaceuticals NASDAQ:CRVS

$4.47 +0.03 (+0.56%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Neurogene stock logo

Neurogene NASDAQ:NGNE

$21.33 -0.33 (-1.52%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Sage Therapeutics stock logo

Sage Therapeutics NASDAQ:SAGE

$8.76 -0.21 (-2.29%)
As of 11:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma stock logo

Vor Biopharma NYSE:VOR

$2.02 -0.04 (-1.71%)
As of 11:34 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.